Hikma Ventures

Prognos Health is a health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables the querying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes, and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

O7 Therapy is revolutionizing access to mental health services through a digital platform and mobile app offering online therapy, psycho-educational resources, and corporate wellness programs, to empower Arabic-speaking people to pursue their mental wellness journey. We use cutting edge AI in a very engaging user experience producing an effective therapeutic journey. Additionally, we provide Employee Wellness Programs for organizations through a unique B2B2E model, prioritizing the impact of mental health challenges in the workplace, and focusing on raising awareness and understanding, reducing stigma and shame, creating safe and supportive spaces, and implementing strategies that promote mental wellbeing.

Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet. Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR), and artificial intelligence (AI). Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.

Altibbi is a digital health platform that offers tools and information to provide access to health advice 24/7 anywhere through its website and apps.

Activ Surgical is a digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes, and accessibility. Its scalable and patent-protected surgical software platform technology is driven by computer vision, artificial intelligence, analytics, and machine learning to enhance a surgeon’s intra-operative decision making, and reduce unintended and preventable surgical complications. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

NuvoAir Medical is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions. NuvoAir’s care model integrates advanced monitoring technology and analytics with evidence-based interventions, all delivered by a multidisciplinary team. This approach ensures that each patient's journey is highly personalized. Collaborating with health plans and risk-bearing entities through flexible, value-based payment arrangements, NuvoAir distinguishes itself as a specialty care provider, effectively reducing healthcare costs and enhancing overall outcomes.

BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline of indications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.

Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers, allowing diabetic patients to monitor their blood glucose levels.

Click Therapeutics, Inc. is a company that develops and commercializes digital therapeutics designed to address unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company focuses on software as prescription medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Click’s innovative Digital Therapeutics™ are intended for use independently or alongside traditional biomedical treatments. The company leverages its Clickometrics® adaptive data science platform to personalize user experiences, enhancing engagement and treatment outcomes. Following a successful clinical trial, its smoking cessation program is widely available across multiple payers and providers. Currently, Click is advancing its lead prescription program into a phase III clinical trial for the treatment of major depressive disorder in adults, further solidifying its position in the digital health space.

Surgery is one of the most vulnerable experiences that a person can ever go through. They find it scary that in the 21st century, they still rely on paper instructions and human memory to get patients through this complicated journey. They can and they must do better. At SeamlessMD, they are on a mission to give every patient the best health outcomes after surgery. Together with healthcare providers, they leverage design, data and technology to enhance the patient experience, improve outcomes and lower costs.

Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.

Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet. Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR), and artificial intelligence (AI). Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.

Winterlight Labs builds technology that can quickly and accurately detect signs of cognitive impairment from a sample of speech. WinterLight Labs develops a novel AI technology platform that can quickly and accurately quantify speech and language patterns to help detect and monitor cognitive and mental diseases. This platform can analyze natural speech to detect and monitor dementia, aphasia, and various cognitive conditions. Using a short one-minute sample of speech, WinterLight can characterize the speaker's cognitive, acoustic, and linguistic state, including lexical diversity, syntactic complexity, semantic content, and articulation. Winterlight was founded in 2015 and is based in Toronto, Canada.

Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health and wellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device.

Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers, allowing diabetic patients to monitor their blood glucose levels.

Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset.

Click Therapeutics, Inc. is a company that develops and commercializes digital therapeutics designed to address unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company focuses on software as prescription medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Click’s innovative Digital Therapeutics™ are intended for use independently or alongside traditional biomedical treatments. The company leverages its Clickometrics® adaptive data science platform to personalize user experiences, enhancing engagement and treatment outcomes. Following a successful clinical trial, its smoking cessation program is widely available across multiple payers and providers. Currently, Click is advancing its lead prescription program into a phase III clinical trial for the treatment of major depressive disorder in adults, further solidifying its position in the digital health space.

Propeller Health is a mobile platform that offers sensors, mobile apps, analytics, and services to support respiratory health management. The HIPAA compliant platform stores users’ data in a cloud computing infrastructure. The Propeller sensor and mobile application help users learn more about and better manage their asthma, COPD, and respiratory disease. The Propeller sensor attaches to users’ inhalers and wirelessly syncs with their smartphones. It tracks their triggers and symptoms and sends personalized feedback and education to their phones based on the symptoms. Users can see how often they use the medication, and set up medication reminders and alerts. Propeller community enables users to share their Propeller data with their physician and family members. Propeller Health is backed by Safeguard Scientifics, The Social+Capital Partnership, California HealthCare Foundation, and other investors. The platform works with organizations such as Dignity Health, Wyckoff Heights Medical Center, Amerigroup Florida, and the City of Louisville. The system has been featured in The Economist, Washington Post, Fast Company, Wired, and Scientific American. Propeller Health has received TEDMED Innovation Showcase, White House Champion of Change, and Bluetooth Breakthrough Product awards. Propeller Health was launched by David Van Sickle, Greg Tracy, and Mark Gehring and its operations are based in Wisconsin, United States.

Prognos Health is a health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables the querying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes, and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers, allowing diabetic patients to monitor their blood glucose levels.

Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.

Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health and wellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device.

Propeller Health is a mobile platform that offers sensors, mobile apps, analytics, and services to support respiratory health management. The HIPAA compliant platform stores users’ data in a cloud computing infrastructure. The Propeller sensor and mobile application help users learn more about and better manage their asthma, COPD, and respiratory disease. The Propeller sensor attaches to users’ inhalers and wirelessly syncs with their smartphones. It tracks their triggers and symptoms and sends personalized feedback and education to their phones based on the symptoms. Users can see how often they use the medication, and set up medication reminders and alerts. Propeller community enables users to share their Propeller data with their physician and family members. Propeller Health is backed by Safeguard Scientifics, The Social+Capital Partnership, California HealthCare Foundation, and other investors. The platform works with organizations such as Dignity Health, Wyckoff Heights Medical Center, Amerigroup Florida, and the City of Louisville. The system has been featured in The Economist, Washington Post, Fast Company, Wired, and Scientific American. Propeller Health has received TEDMED Innovation Showcase, White House Champion of Change, and Bluetooth Breakthrough Product awards. Propeller Health was launched by David Van Sickle, Greg Tracy, and Mark Gehring and its operations are based in Wisconsin, United States.

Chrono Therapeutics (CHRONO) is a pharmaceutical company founded in 2004 with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery (TDD) that offers real-time behavioral support. Chrono’s executive leadership combines years of professional experience and personal passions for developing life-saving medical products. Steeped with years of experience in product development, science, R&D an understanding of the consumer smoking cessation market, FDA approval experience and bringing life-saving products to market, the team represents a wide-array of knowledge that combined can help address the serious epidemic of smoking.